Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

becotatug

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, becotatug targets, binds to and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferation of EGFR-expressing tumor cells. In addition, JMT101 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-EGFR monoclonal antibody JMT101
Code name:	JMT 101 JMT-101 JMT101

becotatug

Search NCI's Drug Dictionary